A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Translational Drug Development
• Collaborators: American Association for Cancer Research; Scottsdale Healthcare; Stand Up To Cancer

Criteria

Inclusion Criteria:

• metastatic adenocarcinoma of the pancreas

• male or non-pregnant female

• 18 years of age or greater

• one prior therapy for the treatment of metastatic disease

• must start continuation therapy within 9 months of starting first line treatment

• have adequate organ and bone marrow function

• must have a Karnofsky performance status greater than or equal to 70

• one or more metastatic tumors measurable by CT scan and accessible for biopsy

Exclusion Criteria:

• operable or locally advanced pancreatic cancer

• metastatic tumor that is not amendable to biopsy

• known brain mets unless previously treated and well controlled

• active, uncontrolled bacterial, viral or fungal infections

• known infection with HIV, hepatitis B or hepatitis C

• pregnant or breast-feeding patients